Ultragenyx’s Evkeeza Receives Positive Recommendation for Homozygous Familial Hypercholesterolemia Treatment in the UK
January 4, 2024
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has recently announced that the National Institute for Health and Care Excellence (NICE) in the UK has issued a final draft guidance recommending the use of Evkeeza (evinacumab) to NHS England. This recommendation comes as a significant development for individuals aged 12 years and older who suffer from homozygous familial hypercholesterolemia (HoFH), a rare and debilitating condition characterized by extremely high levels of low-density lipoprotein-cholesterol (LDL-C) in the blood.
Evkeeza, the first-ever angiopoietin-like 3 (ANGPTL3) inhibitor treatment indicated for HoFH, is now recommended within its marketing authorization as an adjunct to diet and other LDL-C lowering therapies for the management of HoFH in adolescents and adults. This positive recommendation from NICE is a validation of the drug’s effectiveness in addressing the significant unmet medical needs of this patient population.
Homozygous familial hypercholesterolemia affects an estimated 1 in 160,000 people worldwide. It is a genetic disorder inherited from both parents, resulting in the inability of the body to remove LDL-C effectively. This condition significantly increases the risk of cardiovascular disease, including heart attacks and strokes, and can severely impact the quality of life for those affected.
Evkeeza has shown promising results in clinical trials, demonstrating its ability to dramatically reduce LDL-C levels in individuals with HoFH. By inhibiting ANGPTL3, a protein that regulates lipid metabolism, Evkeeza offers a unique mechanism of action to effectively lower cholesterol levels and potentially mitigate cardiovascular risks.
The recommendation of Evkeeza by NICE will now allow eligible patients in the UK to access this life-changing treatment option. With no currently approved therapies specifically designed for HoFH, Evkeeza represents a significant breakthrough for individuals who previously had limited options for managing their condition.
The positive recommendation for Evkeeza aligns with Ultragenyx’s commitment to improving the lives of patients with rare diseases. The company is dedicated to developing and delivering innovative therapies to address unmet medical needs in a variety of genetic disorders.
In conclusion, the recommendation of Evkeeza by NICE marks a promising advancement in the treatment landscape for individuals with HoFH. This significant milestone showcases the potential of Evkeeza as a transformative therapy for patients suffering from this rare and debilitating condition. The availability of Evkeeza in the UK will offer new hope and better outcomes for those affected, setting a precedent for improved management of HoFH globally.
Relevant
Comments